Mineralocorticoid receptor antagonist monotherapy in pediatric non-classical 11β-hydroxylase deficiency

  • Elaine C. Kennedy
  • , Maria Stack
  • , Eirin Carolan
  • , Maeve Durkan
  • , Caroline M. Joyce
  • , Colin P. Hawkes

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Congenital adrenal hyperplasia (CAH) is an uncommon genetic disorder which affects cortisol production in the adrenal glands. It is usually treated with glucocorticoids. We present a case of non-classical CAH caused by the partial deficiency of 11 beta-hydroxylase (11βOH) which was treated with aldosterone antagonist (eplerenone) monotherapy. Case presentation: An adolescent male was diagnosed with 11 beta-hydroxylase deficiency (11βOHD) at 13 years of age when he presented with hypertension, fatigue and headaches. He was initially treated with glucocorticoids, but requested an alternative therapy. Eplerenone was commenced at 25 mg with subsequent dose increases to 100 mg daily. His hypertension was controlled on this regimen, achieving a 24 h average blood pressure of 124/81 mmHg. Conclusions: CAH caused by 11βOHD is a known cause of hypertension. It is usually managed with glucocorticoids, and antihypertensives are added if blood pressure remains uncontrolled. In this case, glucocorticoid therapy was not tolerated and treatment with aldosterone antagonist monotherapy was effective in controlling his hypertension.

Original languageEnglish
Pages (from-to)1100-1103
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume37
Issue number12
DOIs
Publication statusPublished - 1 Dec 2024

Keywords

  • 11 beta-hydroxylase deficiency
  • 11-deoxycortisol
  • congenital adrenal hyperplasia
  • eplerenone

Fingerprint

Dive into the research topics of 'Mineralocorticoid receptor antagonist monotherapy in pediatric non-classical 11β-hydroxylase deficiency'. Together they form a unique fingerprint.

Cite this